<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3024">
  <stage>Registered</stage>
  <submitdate>13/12/2010</submitdate>
  <approvaldate>13/12/2010</approvaldate>
  <nctid>NCT01260779</nctid>
  <trial_identification>
    <studytitle>Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors</studytitle>
    <scientifictitle>Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PV-10-EA-02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory</healthcondition>
    <healthcondition>Approved Alternative Therapy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PV-10 (10% rose bengal disodium)

Treatment: drugs: PV-10 (10% rose bengal disodium)
Intralesional injection for chemoablation of cutaneous or subcutaneous lesions

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>1. Age 18 years or older, male or female.

          2. Histologically or cytologically confirmed cancer where there is no comparable or
             satisfactory approved alternative therapy specific to cutaneous or subcutaneous
             tumors.

          3. Performance Status: ECOG 0-2.

          4. Life Expectancy: At least 6 months.

          5. Blood Chemistry:

               -  Creatinine = 3 times the upper limit of normal (ULN).

               -  Total bilirubin = 3 times the upper limit of normal (ULN).

               -  AST/ALT/ALP = 5 times the upper limit of normal (ULN).

          6. Thyroid Function

               -  Total T3 or free T3 (serum triiodothyronine), total T4 or free T4 (serum
                  thyroxine) and THS (serum thyrotropin) = grade 2 abnormality.

          7. Renal Function

               -  Subjects must have adequate renal function in the opinion of the Investigator
                  with no clinically significant renal impairment or uncontrolled renal disease.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer />
    <exclusivecriteria>1. Cancer patients who are eligible for an existing PV-10 clinical trial.

          2. Certain photosensitizing agents within 5 half-lives prior to PV-10 administration.

          3. Concurrent or Intercurrent Illness:

               -  Subjects with uncontrolled diabetes or extremity complications due to diabetes.

               -  Subjects with severe peripheral vascular disease.

               -  Subjects with significant concurrent or intercurrent illness, psychiatric
                  disorders, or alcohol or chemical dependence that would, in the opinion of the
                  Investigator, compromise their safety or compliance or interfere with
                  interpretation of study results.

               -  Subjects with uncontrolled thyroid disease, goiter, partial thyroidectomy,
                  radioiodine- or surgically-treated Graves' hyperthyroidism or cystic fibrosis.

               -  Subjects with clinically significant acute or unstable cardiovascular, (stroke),
                  renal, gastrointestinal, pulmonary, immunological (with the exception of the
                  presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine,
                  or central nervous system disorders.

          4. Pregnancy:

               -  Female subjects who are pregnant or lactating.

               -  Female subjects who have positive serum ÃŸHCG pregnancy test taken within 7 days
                  of PV-10 administration.

               -  Fertile subjects who are not using effective contraception.

          5. Investigational Agents:

               -  Subjects who have received investigational agents within 4 weeks (or 5
                  half-lives) of study administration.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Expanded Access</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>No longer available</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>Melanoma Institute Australia - Sydney (North Sydney and Camperdown)</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Royal Adelaide Hospital Cancer Centre - Adelaide</hospital>
    <postcode> - Sydney (North Sydney and Camperdown)</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode> - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Provectus Biopharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This compassionate use protocol provides expanded access for investigational use of PV-10 in
      cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is
      no comparable or satisfactory approved alternative therapy and whom, in the opinion of the
      investigator, may benefit from PV-10 administration.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01260779</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>